Literature DB >> 28597949

Primary islet autoantibody at initial seroconversion and autoantibodies at diagnosis of type 1 diabetes as markers of disease heterogeneity.

Jorma Ilonen1, Johanna Lempainen1,2, Anna Hammais1, Antti-Pekka Laine1, Taina Härkönen3,4, Jorma Toppari2,5, Riitta Veijola6, Mikael Knip3,4,7,8.   

Abstract

OBJECTIVE: The relationship between patterns of islet autoantibodies at diagnosis and specificity of the first islet autoantibody at the initiation of autoimmunity was analyzed with the aim of identifying patterns informative of the primary autoantibodies.
METHODS: Information about a single first autoantibody at seroconversion and autoantibody data at diagnosis were available for 128 children participating in the follow-up cohort of the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study. Autoantibody data at diagnosis and genotyping results were also obtained from children in the Finnish Pediatric Diabetes Register (FPDR).
RESULTS: Insulin autoantibodies (IAA) were the most common primary antibodies (N = 68), followed by those for glutamic acid decarboxylase (GADA; N = 38), IA-2 antigen (IA-2A; N = 13), and zinc transporter 8 (ZnT8A; N = 9), whereas at diagnosis, IA-2A were most frequent (N = 103), followed by IAA (N = 78), ZnT8A (N = 73), and GADA (N = 71). Accordingly, the presence of many specific autoantibodies at diagnosis was due to the secondary antibodies appearing after primary antibodies, and in some cases, the primary autoantibody, most often IAA, had already disappeared at the time of diagnosis. Many of the autoantibody combinations present at diagnosis could be assembled into groups associated with either IAA or GADA as first autoantibodies. These combinations, in children diagnosed below the age of 10 years in the FPDR, were found to be strongly associated with risk genotypes in either INS (IAA first) or IKZF4-ERBB3 (GADA first) genes.
CONCLUSIONS: Autoantibody patterns at diagnosis may be informative on primary autoantibodies initiating autoimmunity in young children developing type 1 diabetes.
© 2017 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd.

Entities:  

Keywords:  disease heterogeneity; genetics; islet autoantibodies; type 1 diabetes

Mesh:

Substances:

Year:  2017        PMID: 28597949     DOI: 10.1111/pedi.12545

Source DB:  PubMed          Journal:  Pediatr Diabetes        ISSN: 1399-543X            Impact factor:   4.866


  11 in total

Review 1.  Shared and unique immune alterations in pre-clinical autoimmunity.

Authors:  Samantha Slight-Webb; Rebecka L Bourn; V Michael Holers; Judith A James
Journal:  Curr Opin Immunol       Date:  2019-09-23       Impact factor: 7.486

2.  Introducing the Endotype Concept to Address the Challenge of Disease Heterogeneity in Type 1 Diabetes.

Authors:  Manuela Battaglia; Simi Ahmed; Mark S Anderson; Mark A Atkinson; Dorothy Becker; Polly J Bingley; Emanuele Bosi; Todd M Brusko; Linda A DiMeglio; Carmella Evans-Molina; Stephen E Gitelman; Carla J Greenbaum; Peter A Gottlieb; Kevan C Herold; Martin J Hessner; Mikael Knip; Laura Jacobsen; Jeffrey P Krischer; S Alice Long; Markus Lundgren; Eoin F McKinney; Noel G Morgan; Richard A Oram; Tomi Pastinen; Michael C Peters; Alessandra Petrelli; Xiaoning Qian; Maria J Redondo; Bart O Roep; Desmond Schatz; David Skibinski; Mark Peakman
Journal:  Diabetes Care       Date:  2019-11-21       Impact factor: 19.112

Review 3.  Serum biomarkers for diagnosis and prediction of type 1 diabetes.

Authors:  Lian Yi; Adam C Swensen; Wei-Jun Qian
Journal:  Transl Res       Date:  2018-08-01       Impact factor: 7.012

4.  Strength in Numbers: Opportunities for Enhancing the Development of Effective Treatments for Type 1 Diabetes-The TrialNet Experience.

Authors:  Carla J Greenbaum; Cate Speake; Jeffrey Krischer; Jane Buckner; Peter A Gottlieb; Desmond A Schatz; Kevan C Herold; Mark A Atkinson
Journal:  Diabetes       Date:  2018-05-16       Impact factor: 9.461

Review 5.  Immunological biomarkers for the development and progression of type 1 diabetes.

Authors:  Chantal Mathieu; Riitta Lahesmaa; Ezio Bonifacio; Peter Achenbach; Timothy Tree
Journal:  Diabetologia       Date:  2018-09-12       Impact factor: 10.122

6.  Clinical features, biochemistry, and HLA-DRB1 status in youth-onset type 1 diabetes in Sudan.

Authors:  Tomader Ali Mohammed Ibrahim; Denira Govender; Mohamed Ahmed Abdullah; Janelle Annette Noble; Mohammed Osman Hussien; Julie Ann Lane; Steven John Mack; Gregory George Noble Martin; Mark Alvin Atkinson; Clive Henry Wasserfall; Graham David Ogle
Journal:  Pediatr Diabetes       Date:  2021-04-20       Impact factor: 3.409

7.  Class II HLA Genotype Association With First-Phase Insulin Response Is Explained by Islet Autoantibodies.

Authors:  Maarit K Koskinen; Johanna Lempainen; Eliisa Löyttyniemi; Olli Helminen; Anne Hekkala; Taina Härkönen; Minna Kiviniemi; Olli Simell; Mikael Knip; Jorma Ilonen; Jorma Toppari; Riitta Veijola
Journal:  J Clin Endocrinol Metab       Date:  2018-08-01       Impact factor: 5.958

8.  The Evolving Landscape of Autoantigen Discovery and Characterization in Type 1 Diabetes.

Authors:  Anthony W Purcell; Salvatore Sechi; Teresa P DiLorenzo
Journal:  Diabetes       Date:  2019-05       Impact factor: 9.461

9.  Heterogeneity of beta-cell function in subjects with multiple islet autoantibodies in the TEDDY family prevention study - TEFA.

Authors:  Maria Månsson Martinez; Lampros Spiliopoulos; Marlena Maziarz; Carina Törn; Falastin Salami; Daniel Agardh; Jorma Toppari; Åke Lernmark; Jukka Kero; Riitta Veijola; Päivi Tossavainen; Sauli Palmu; Markus Lundgren; Henrik Borg; Anastasia Katsarou; Helena Elding Larsson; Mikael Knip
Journal:  Clin Diabetes Endocrinol       Date:  2022-01-05

10.  Dynamics of Islet Autoantibodies During Prospective Follow-Up From Birth to Age 15 Years.

Authors:  Petra M Pöllänen; Samppa J Ryhänen; Jorma Toppari; Jorma Ilonen; Paula Vähäsalo; Riitta Veijola; Heli Siljander; Mikael Knip
Journal:  J Clin Endocrinol Metab       Date:  2020-12-01       Impact factor: 5.958

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.